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cancer cells with alternative 
lengthening of Telomeres Do not 
Display a general hypersensitivity 
to aTr inhibition
Katharina I. Deeg, Inn Chung, Caroline Bauer and Karsten Rippe*
Research Group Genome Organization & Function, German Cancer Research Center (DKFZ) and Bioquant Center, 
Heidelberg, Germany
Telomere maintenance is a hallmark of cancer as it provides cancer cells with cellular  
immortality. A significant fraction of tumors uses the alternative lengthening of telo-
meres (ALT) pathway to elongate their telomeres and to gain an unlimited proliferation 
potential. Since the ALT pathway is unique to cancer cells, it represents a potentially 
valuable, currently unexploited target for anti-cancer therapies. Recently, it was 
proposed that ALT renders cells hypersensitive to ataxia telangiectasia- and RAD3-
related (ATR) protein inhibitors (Flynn et al., Science 347, 273). Here, we measured the 
response of various ALT- or telomerase-positive cell lines to the ATR inhibitor VE-821. 
In addition, we compared the effect of the inhibitor on cell viability in isogenic cell 
lines, in which ALT was active or suppressed. In these experiments, a general ATR 
inhibitor sensitivity of cells with ALT could not be confirmed. We rather propose that 
the observed variations in sensitivity reflect differences between cell lines that are 
unrelated to ALT.
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inTrODUcTiOn
Cancer cells need to maintain their telomeres to avoid cellular senescence and apoptosis induced 
by the replicative shortening of chromosome ends. Frequently, expression of TERT, the protein 
subunit of telomerase, is reactivated to extend the telomeres. In addition, a significant fraction 
of tumors elongates the telomeres by an alternative lengthening of telomeres (ALT) pathway that 
operates via DNA repair and recombination processes as reviewed previously (1, 2). ALT is not 
known to occur in healthy cells and, thus, represents a unique feature of cancer cells that could be 
targeted with specific drugs.
A recent study investigated telomerase-positive and ALT-positive osteosarcoma and lung cancer 
cell lines as well as glioma stem cell lines and reported that cells that employ the ALT pathway 
are hypersensitive to the inhibition of the protein kinase ataxia telangiectasia- and RAD3-related 
protein (ATR), one of the two main DNA damage checkpoint-activating kinases in human cells 
(3). The authors concluded that treatment with the ATR inhibitor VE-821 selectively kills ALT 
cells within 6  days. They proposed that the immediate cell death induced by ATR inhibition 
in ALT cells is caused by an accumulation of DNA damage, aberrant anaphase chromosome 
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segregation, and increased micronuclei formation. Yet, how ATR 
inhibition elicits these effects specifically in ALT cells to affect 
the short-term cell viability remains elusive. Previously, several 
studies have demonstrated that inhibiting telomerase or ALT will 
induce senescence or cell death, e.g., Ref. (4–7). However, in the 
latter work many population doublings over weeks and months 
were required to elicit this type of response. This long-term 
response is in line with the view that no significant effects on 
cell viability due to telomere shortening are expected to occur 
within a few days.
Here, we recapitulated the cell viability and FACS experiments 
by Flynn et  al. using various ALT- or telomerase-positive cell 
lines. Additionally, we investigated whether suppression of ALT 
activity affects cell viability upon treatment with ATR inhibitor. 
In our study, no general hypersensitivity of ALT-positive cells 
toward ATR inhibitors was observed.
MaTerials anD MeThODs
cell culture
Validated U2OS, HeLa, CAL72, HCT116, and SAOS2 cells were 
obtained from the German Collection of Microorganisms and 
Cell Cultures (DSMZ, Braunschweig, Germany). The MG63 cell 
line was purchased from CLS Cell Lines Service (Eppelheim, 
Germany). U2OS, HeLa, and CAL72 cells were maintained in 
DMEM supplemented with 10% FCS, 2  mM l-glutamine, 1% 
antibiotics. For CAL72, 1X ITS liquid media supplement (Sigma-
Aldrich) was added to this medium. The other three cell lines 
studied were cultured in 90% McCoy’s 5A supplemented with 
10% FCS, 2 mM l-glutamine, and 1% antibiotics (HCT116), in 
85% McCoy’s 5A supplemented with 20% FCS (SAOS2) or in 
DMEM/Ham’s F12 medium supplemented with 5% FCS, 2 mM 
l-glutamine, and 1% antibiotics (MG63). An U2OS cell line for 
inducible expression of ATRX (referred to here as U2OSATRX-2) was 
kindly provided by Richard Gibbons (University of Oxford, UK) 
and has been described previously (8). The U2OSATRX-2 cells were 
cultured in DMEM supplemented with 10% doxycycline-free 
FCS, 2 mM l-glutamine, 1% antibiotics, 0.5 μg/ml puromycin, 
0.7 μg/ml G418.
cell Viability assays
For cell viability assays, cells were seeded in triplicate in 96-well 
plates and incubated overnight. Different cell numbers were 
seeded to determine the cell number needed to obtain 70–90% 
confluency of the control sample after 6  days. Optimal start-
ing cell numbers for U2OS, HeLa, HCT116, and MG63 were 
500 cells, and for CAL72 and SAOS2 1500 cells. The following day 
cells were either treated with DMSO (control) or with increasing 
concentrations (0.5, 1, 2, 4, 8, and 16 μM) of the ATR inhibitor 
VE-821 dissolved in DMSO. Three different batches were com-
pared that included VE-821 as a predissolved 10  mM solution 
or as a powder obtained from Selleckchem as well as VE-821 
in powder form from Calbiochem/Merck. The three different 
VE-821 batches yielded undistinguishable dose–response curves 
when compared for the same reference cell samples. The com-
pound from Selleckchem was used for the experiments presented 
here. Cells were incubated for 6 days without medium change and 
cell viability was analyzed using CellTiter Glo (Promega) and a 
TECAN Infinite M200 plate reader according to the manufactur-
ers’ instructions.
Facs analysis of cell Death
For analysis of cell death, cells were seeded in T25 flasks. Cell 
numbers were adjusted for each cell line to account for vary-
ing proliferation rates (1 ×  105 CAL72 cells, 1.4 ×  105 SAOS2 
cells, and 0.8 ×  105 cells for HeLa, HCT116, and U2OS). The 
following day each cell line was either treated with 3 μM VE-821 
(Selleckchem) or with the same volume of DMSO for the con-
trol samples. Cells were incubated for 6 days without medium 
change. Cells, including dead cells, were collected by trypsin 
and total cell numbers were determined using the LUNA cell 
counter (Biozym). Cells were resuspended in FACS binding 
buffer (10 mM HEPES, 2.5 mM CaCl2, 140 mM NaCl) at a final 
concentration of 2 × 106 cells/ml, stained with FITC annexin V 
(BioLegend) and propidium iodide (Miltenyi Biotec) accord-
ing to the manufacturers’ instructions, and analyzed by flow 
cytometry on a FACS Canto II (BD Biosciences). The fraction of 
apoptotic cells, characterized as annexin V positive, was quanti-
fied using the FACS Diva software. The percentage of induced 
cell death dind was calculated as
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generation and analysis of a U2Os cell 
line with inducible aTrX expression
The pEGFP-C2-ATRX-HA plasmid was kindly provided by 
David Picketts (University of Ottawa, Canada) (9). ATRX-HA 
was amplified and cloned into the pTRE3G-ZSGreen1 vector 
(Clontech, USA) to construct pTRE3G-ZSGreen1-ATRX-HA 
for doxycycline-inducible expression of ATRX. Plasmids that 
contained the ATRX cDNA were propagated in the dam/dcm-
negative bacteria strain JM110 (Agilent Technologies) to avoid 
transposon insertions. A stable U2OSATRX-1 cell line was gener-
ated by transfecting U2OS cells with pCMV-Tet3G (Clontech, 
USA) and pTRE3G-ZSGreen1-ATRX-HA and subsequent 
selection with G418 (1 mg/ml). U2OSATRX-1 cells were cultured 
under the same conditions as the parental U2OS cell line except 
that doxycycline-free FCS was used. For induction of ATRX 
expression, 1 μg/ml doxycycline was added to the medium and 
the expression was evaluated by western blotting. The following 
antibodies were used: anti-ATRX (Sigma, HPA001906), anti-HA 
(Abcam, ab18181), and anti-GAPDH (Ambion, AM4300). ALT 
activity after ATRX expression was evaluated by the C-circle 
assay and the number of ALT-associated PML bodies (APBs) 
as described previously (10). U2OSATRX-1 (−) and U2OSATRX-1 
(+) cells were cultured in the absence or presence of 1 μg/ml 
doxycycline, respectively, for at least 7 days before treatment with 
ATR inhibitor. For the cell viability assay, 1000 cells of U2OSATRX-1 
(−) and U2OSATRX-1 (+) were initially seeded and treated with 
inhibitor as described above. The same conditions were used 
for cell viability assays with the U2OSATRX-2 cell line that, for 
FigUre 1 | cell viability of alT- and telomerase-positive (Tel) cell lines upon treatment with the aTr inhibitor Ve-821.  
(Continued)
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FigUre 1 | continued
(a) Different cell numbers of HCT116 (TEL) cells were seeded in a 96-well plate and treated with increasing concentrations of the ATR inhibitor VE-821 for 6 days to 
determine the influence of the starting cell number on the cell viability assay. Cell viability was analyzed using CellTiter Glo and is depicted as percentage of control 
(n = 3). (B) Same as panel A but for the U2OS ALT cell line. (c) Analysis of cell viability for different cell lines with starting cell numbers that led to 70–90% 
confluency after 6 days in the absence of inhibitor (n = 3). Cell numbers used for seeding were 500 cells/well for U2OS, HeLa, HCT116, and MG63 and 1500 cells/
well for the CAL72 and SAOS2 cell lines. Error bars represent SD of triplicate experiments. (D) IC50 concentrations determined from cell viability curves shown in 
panel C. (e) FACS analysis of cell death fraction in ALT and TEL cell lines treated with 3 μM VE-821 for 6 days in comparison to the DMSO control. Dead cells were 
determined by annexin V staining. Error bars represent SEM (n = 3). (F) Percentage of induced cell death determined from FACS analysis as in panel E. The induced 
cell death fraction was calculated as described in the section “Materials and Methods.”
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evaluating the ATRX rescued state, was induced with 0.4 μg/ml 
doxycycline for 7 days.
resUlTs anD DiscUssiOn
To evaluate the sensitivity of cell lines to ATR inhibition, we 
compared the human telomerase positive (“TEL”) cell lines HeLa, 
HCT116, and MG63 with the ALT cell lines U2OS, CAL72, and 
SAOS2. Cell viability measurements after treatment with different 
ATR inhibitor concentrations were conducted using the CellTiter 
Glo assay (Promega) and by fluorescence-activated cell sorting 
(FACS) analysis with annexin V staining. The experimental 
methods and inhibitor treatment conditions of 6 days incubation 
without medium change were those used previously by Flynn 
et  al. who also studied the MG63, U2OS, CAL72, and SAOS2 
osteosarcoma cell lines (3).
cell Viability analysis with  
the cellTiter glo assay
In order to measure cell viability in response to VE-821, we first 
examined the HCT116 TEL cell line (Figure  1A) in reference 
to the original paper that characterized the VE-821 inhibitor 
(11). It is noted that the CellTiter Glo assay measures changes 
in the number of viable cells after inhibitor treatment relative 
to a control sample. Whether the resulting differences originate 
from a reduced growth rate or from an increase in cell death can-
not be distinguished in this assay. The half-maximal inhibitory 
concentration (IC50) for the HCT116 cell line in our experiments 
was 1–2 μM and similar to that reported previously [see Figure 
S4D in Ref. (11)]. We note that the results were dependent on the 
amount of cells initially seeded (Figure 1A). Seeding higher cell 
numbers shifted the dose–response curve to elevated inhibitor 
concentrations. Consequently, the cells appeared less sensitive 
to the inhibitor. The same dependence was observed for the 
U2OS ALT cell line (Figure 1B). This behavior is likely to reflect 
the well-known differences between cell lines in terms of their 
proliferation rate as well as the dependence of this parameter on 
cell density. For example, cells can appear less sensitive to the 
ATR inhibitor when starting with higher cell numbers because 
the proliferating control cells reach confluency and stop dividing 
before the treatment ends after 6 days. By contrast, cells growing 
slower upon treatment may not reach confluency within 6 days 
and continue to proliferate during the complete observation 
period, albeit at a lower rate. Since values are normalized to the 
control, this would make the ratio of viable cells in treated versus 
control samples dependent on the density of seeded cells, the 
proliferation rate, and the observation time.
aTr inhibitor sensitivity of 
Different cell lines
For comparing ALT and TEL cell lines, we selected a starting cell 
number for each cell line that led to 70–90% confluency after 
6 days in the absence of the inhibitor. The optimized starting cell 
numbers used for U2OS, HeLa, HCT116, and MG63 were 500 
cells, and for the slower growing CAL72 and SAOS2 cell lines 
1500 cells/well of a 96-well plate. Using these seeding cell num-
bers, we found no hypersensitivity of ALT cell lines in response 
to the VE-821 ATR inhibitor (Figure 1C). Instead, the sensitivity 
varied between cell lines irrespective of the telomere maintenance 
mechanism. While the HCT116 TEL and the CAL72 ALT cell 
lines were sensitive to ATR inhibition at VE-821 concentrations 
of 1–2 μM, the MG63 TEL and the SAOS2 ALT cell lines showed 
a stronger reduction of viable cells only at higher inhibitor con-
centration. The IC50 value measured ranged from 0.9 to 3.3 μM 
for the TEL cell lines and from 0.7 to 7 μM for the ALT cell lines 
(Figure  1D). Thus, the IC50 values of the two groups were not 
systematically different, but rather showed a high variation within 
each group.
Next, we quantified dead cells by FACS analysis of annexin V 
stained telomerase- and ALT-positive cells treated with 3  μM 
VE-821 for 6 days (Figures 1E,F). Measurements of the SAOS2 
ALT cell line and the HeLa TEL cell line revealed a fraction of 
40% dead cells already in the control samples in the absence of 
inhibitor (Figure  1E). This indicates that these cells are more 
sensitive to 6  days of culturing without medium change. In 
comparison to the control, the CAL72 ALT cell line displayed 
the highest sensitivity to ATR inhibitor treatment in this assay, 
while the MG63 TEL cells were mostly insensitive as reflected 
by the calculated percentages of induced cell death in relation 
to the control (Figure  1F). However, treatment with the ATR 
inhibitor induced a higher percentage of cell death in the HeLa 
and HCT116 TEL cell lines compared to the U2OS ALT cells. 
Thus, we did not observe a selective killing of ALT cells by ATR 
inhibition in these experiments.
aTr inhibitor sensitivity in 
Dependence of alT activity
To evaluate the effect of ALT activity on ATR sensitivity in an 
isogenic cell line and independent of the above-mentioned 
confounding factors, we exploited the recent finding that the 
α-thalassemia mental retardation X-linked (ATRX) chro-
matin remodeling protein acts as a suppressor of ALT (8, 12). 
Accordingly, a cell line for the doxycycline-inducible expression of 
ectopic ATRX in the U2OS ALT cell line that intrinsically harbors 
(a) Western blot showing the expression of HA-tagged ATRX in the 
generated U2OSATRX-1 cell clone upon doxycycline induction for 48 h and a 
HeLa reference. In addition to the full-length ATRX band at about 260 kDa, 
shorter ATRX variants between 200 and 220 kDa were also detected in the 
HA blot that might correspond to degraded or alternatively spliced products 
of ATRX, as described previously (15, 16). (B) Average number of APBs per 
cell in uninduced and for 7 days induced U2OSATRX-1 cells (n = 350) analyzed 
by 3D confocal image analysis of PML immunofluorescence and telomere 
FISH stainings as described previously (10). (c) C-circle assay as a marker 
of ALT activity in uninduced and induced U2OSATRX-1 cells. Samples without 
polymerase (no pol) and uninduced U2OSATRX-1 were included as controls. 
The bar plot shows a quantification of C-circle levels in uninduced and 
induced U2OSATRX-1 cells from three experiments. (D) ATR inhibitor sensitivity 
in dependence of ALT activity in the U2OSATRX-1 cell line. ATRX-induced 
U2OSATRX-1 (+) and uninduced U2OSATRX-1 (−) cells were analyzed using the 
CellTiter Glo assay in the presence of increasing concentrations of the ATR 
inhibitor VE-821 for 6 days. No changes in ATR inhibitor sensitivity were 
observed when ALT was silenced by ATRX expression. (e) Western blot 
showing the expression of ATRX in the U2OSATRX-2 cell line from (8) after 
induction for 7 days. (F) C-circle assay to test ALT activity in U2OSATRX-2 after 
7 and 13 days of doxycycline induction. Samples without polymerase (no 
pol) and from uninduced cells were included as controls. (g) ATR inhibitor 
sensitivity in U2OSATRX-2 with (-ATRX) and without ALT activity (+ATRX). The 
viability assay was performed as described in the legend to panel D. No 
changes in ATR inhibitor sensitivity were observed when ALT was silenced 
by ATRX expression.
FigUre 2 | continued
FigUre 2 | alT features and sensitivity to aTr inhibitor treatment 
upon ectopic expression of aTrX in aTrX-deficient U2Os cells.  
(Continued)
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large deletions in the ATRX gene was established. In the resulting 
U2OSATRX-1 cell line, HA-tagged ATRX protein is produced upon 
induction as confirmed by western blotting using an ATRX- and 
an HA-specific antibody (Figure 2A). The expression of ATRX 
protein progressively reduced ALT activity as apparent from 
monitoring two characteristic ALT markers: single-stranded 
circular C-rich extrachromosomal telomere repeats (C-circles) 
as well as PML-telomere colocalizations, termed APBs (13, 14). 
After 7  days of ATRX expression, the number of APBs was at 
the background level observed for TEL cell lines (Figure  2B) 
and C-circles were almost undetectable (Figure 2C) indicating a 
complete inhibition of ALT activity. Next, we compared the ATR 
inhibitor sensitivity of U2OSATRX-1 (+) cells that had ALT silenced 
due to ATRX induction to the same U2OSATRX-1 (−) uninduced 
cell line with an active ALT pathway. The dose–response curves 
for the two cell samples were identical as determined with the 
CellTiter Glo assay (Figure 2D). In order to corroborate these 
results, we tested another U2OS cell line referred to here as 
U2OSATRX-2, which was also engineered to express ATRX upon 
doxycycline treatment and has been demonstrated to suppress 
ALT upon ATRX induction (8). In line with the data previously 
published by Clynes et  al., 7  days of doxycycline treatment 
resulted in robust ATRX expression and suppression of the ALT 
pathway as indicated by the absence of C-circles (Figures 2E,F). 
Comparing the ATR inhibitor sensitivity of this cell line when 
ALT was active (no doxycycline) with the same cell line, in which 
ALT was suppressed (+doxycycline) yielded no differences 
(Figure  2G). The dose–response curves of the (un)induced 
U2OSATRX-1 and U2OSATRX-2 cells were indistinguishable within 
the error of the measurements. Thus, silencing ALT activity via 
ectopic expression of ATRX did not affect ATR inhibitor sensitiv-
ity of the cells.
6Deeg et al. ALT Specific ATR Inhibitor Sensitivity
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cOnclUsiOn
Ataxia telangiectasia- and RAD3-related and the protein kinase 
ataxia telangiectasia mutated (ATM) are the two main DNA 
damage checkpoint-activating kinases in human cells. Consistent 
with the view that replication stress and misguided DNA repair 
synthesis are crucial features of ALT, it was found that inhibition 
of ATR or ATM decreases ALT activity (3, 10, 17, 18). However, 
except for the Flynn et  al. study, no immediate ALT-specific 
effects after ATR and/or ATM inhibition on cell viability and 
proliferation on the time scale of several days have been reported.
In our comparison of different cell lines, we identified a 
number of factors that affected the apparent sensitivity toward 
the VE-821 ATR inhibitor but were unrelated to ALT (Figure 1). 
These included the initial cell number seeded in relation to the 
proliferation rate as well as differences in the genetic background 
that may lead to an increased ATR inhibitor sensitivity inde-
pendent of ALT. For example, the telomerase-positive HCT116 
colon cancer cell line used here harbors a mutation in MRE11, 
which impairs binding to NBS1 and Rad50 and suppresses ATM 
activation in response to replication stress (19, 20). This may 
account for its relatively high sensitivity toward ATR inhibition 
in terms of cell viability independent of its telomere maintenance 
mechanism.
In addition to the effects of the above-mentioned factors, it 
would still be conceivable that the presence of ALT contributes 
to an increased sensitivity to ATR inhibition. To address this 
possibility, we compared two U2OS cell lines in which ALT was 
active with the same cell line that had ALT silenced by induc-
ing ectopic ATRX expression. In these experiments, the ATR 
inhibitor sensitivity was not changed when the ALT pathway was 
rendered inactive (Figure  2). Thus, we conclude that cells that 
employ ALT to maintain their telomeres are not generally more 
sensitive to ATR inhibition than telomerase positive cells on the 
time scale of days. Rather we suggest that, as described above, 
the cell line-specific genetic background and additional factors 
exist that are responsible for the different cellular response to ATR 
inhibition.
Our results indicate that ATR inhibition alone will not be suf-
ficient to target tumors in which ALT is active. Nevertheless, we 
share the view that the misguided DNA repair and recombination 
mechanism active in ALT provides unique novel options for anti-
cancer therapies. In this context, the recurrent inactivation of the 
ATRX tumor suppressor protein in ALT cancer samples could be 
exploited (21). As inactive ATRX is associated with ALT-specific 
tumor features, it could, for example, be targeted by synthetic 
lethality approaches. In support of this conclusion, it has been 
recently shown that ATRX deficiency impairs non-homologous 
end joining and increases sensitivity to DNA damaging agents in 
a glioma mouse model (22). A systematic further investigation 
of this relation appears to be promising for exploiting ALT-
associated cellular deregulation in personalized cancer therapies.
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